Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy

Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy is a phase 2, interventional study registered as NCT06691594 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 20 participants, started 2025-02 and due to reach its primary completion in 2028-11. Interventions recorded: neoadjuvant SBRT combined with PD-1 monoclonal antibody and chemotherapy. Conditions listed: Breast Cancer Invasive. Triple-negative eligibility wording from the registry: "Triple-negative breast cancer with PD-L1 CPS \< 10". No results are recorded here; the registry entry is the source.